| Sanofi-Aventis (Suisse) SA - Efluelda TIV 0.5 mL, suspension injectable en seringue pré-remplie | | 69863 | | 01 | | Efluelda TIV 0.5 mL | | suspension injectable en seringue pré-remplie | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 07.04.2025 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 60 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Thailand/8/2022 (H3N2)-like: reassortant virus SAN-022 derived from A/California/122/2022) 60 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: derived from B/Michigan/01/2021 (Victoria lineage) wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.96 mg. | | Packungsbestandteile | | | | | | | | Active Agent | Dose |
|---|
| | 60µg / 0.5ml | | | 60µg / 0.5ml | | | 60µg / 0.5ml |
| | | | Inactive agents |
|---|
| Disodium Phosphate | | Sodium Chloride | | Sodium Dihydrogenophosphate Anhydrate | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | PR | PR | B | | Yes | | 002 | 10 | PR | PR | B | | Yes |
|
|
